|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online December 11, 2006
doi: 10.1242/10.1242/jcs.03303
Commentary |
1 Department of Molecular Medicine, National Public Health Institute (KTL), Biomedicum, P.O.Box 104, FI-00251 Helsinki, Finland
2 Institute of Biomedicine/Anatomy, University of Helsinki, P.O. Box 63, FI-00014, Finland
* Author for correspondence (e-mail: vesa.olkkonen{at}ktl.fi)
Accepted 27 September 2006
 |
Summary |
|---|
 Top Summary IntroductionDefects of the machinery...Disorders that disturb the...Defects in the tethering,...Conclusions and future...References |
|---|
Key words: Disease, Disorder, Genetic, Membrane trafficking, Vesicle transport
|
Introduction |
|---|
|
TopSummaryIntroductionDefects of the machinery...Disorders that disturb the...Defects in the tethering,...Conclusions and future...References |
|---|
Most membrane and secretory proteins, as well as many lipids, are synthesized in the endoplasmic reticulum, whose luminal environment is especially suited to facilitate the proper folding of the synthesized proteins and the initial steps of N-linked glycosylation. Proteins that are destined for transport out of the ER move on to the Golgi complex, where they obtain further post-translational modifications. Subsequently, the proteins are sorted for different destinations: the plasma membrane, regulated secretory granules or vesicles, or organelles of the endocytic pathway (Bard and Malhotra, 2006
; McNiven and Thompson, 2006). This anterograde flow is counterbalanced by retrograde trafficking, which is essential for the maintenance of organelle homeostasis and re-use of components of the trafficking machineries (Sannerud et al., 2003). Within the endocytic pathway, the internalized molecules are also efficiently sorted: selected molecules are returned to the cell surface (e.g. recycling receptors), whereas others (e.g. receptors to be downregulated or compounds to be degraded) are transported to late endosomes and lysosomes, which are responsible for the degradation of internalized material (Maxfield and McGraw, 2004). The out-going and in-coming trafficking pathways communicate through bidirectional transport between the Golgi complex and endosomes (Bonifacino and Rojas, 2006).
In principle, the consecutive steps in the vesicle-mediated exchange of material consist of the same stages irrespective of the particular donor and acceptor membranes in question. These stages include sorting of proteins and lipids, formation of transport carriers, movement of the vesicles along cytoskeletal filaments, recognition of the target organelle, and fusion of the vesicles with the acceptor compartment (Bonifacino and Glick, 2004).
Cell biologists view the molecular machinery that drives intracellular membrane trafficking as a central molecular network that maintains cell viability and organelle functionality and, as such, a key area of basic research. Since the 1990s, an increasing number of human inherited disorders have been shown to be due to defects in genes encoding components of this apparatus. This has provided us with useful arguments in grant applications. However, one should not underestimate the additional value of such research. It not only helps us to understand the molecular mechanisms underlying specific inherited diseases but also provides insight into the function of the transport apparatus in the context of the entire mammalian organism. (1) It specifies in which cell- or tissue-specific processes a given component forms a `critical point'. (2) It yields insight into the functional redundancy in the transport apparatus. (3) It gives us an idea of the compensatory mechanisms that could alleviate the consequences of a defect.
Seven years ago, we surveyed the known genetic disorders of the membrane transport machinery (Olkkonen and Ikonen, 2000). These were then restricted to disorders affecting well-established components of the trafficking machinery or disorders in which there was good reason to believe that the defective protein belongs to the transport apparatus and the cellular phenotype indicates a trafficking defect. The number of diseases clearly satisfying this definition was then nine. A search of the PubMed and online Mendelian inheritance in man (OMIM) databases using the same criteria now yields 30 diseases or groups of closely related disorders. These can be organized in three categories: defects of the machinery responsible for cargo sorting and transport vesicle formation (Table 1, Category A); disorders that disturb the movement of transport carriers along cytoskeletal tracks (Table 1, Category B); and defects in the tethering, docking and fusion of vesicles at the target membrane (Table 1, Category C). In this Commentary, we concentrate on human diseases studied most at the cell biological level and those representing good examples of how the investigation of disease genes has improved our understanding of intracellular transport. We apologize to researchers whose work is not cited herein owing to the incompleteness of our search method or space limitations.
|
|
Defects of the machinery responsible for cargo sorting and transport vesicle biogenesis |
|---|
|
TopSummaryIntroductionDefects of the machinery...Disorders that disturb the...Defects in the tethering,...Conclusions and future...References |
|---|
). The sorting signals include specific amino acid determinants, saturated fatty acyl moieties, and carbohydrates recognized by lectin-like receptors.
There are two types of inherited disease in which these signals or the machinery that recognizes them is directly affected. Mucolipidosis II (I-cell disease) and related milder disorders, characterized by leakage of multiple lysosomal hydrolases from cells and lysosomal deposits of undegraded material, result from a defect in the sorting of multiple lysosomal proteins. In these diseases, the activity of the Golgi enzyme N-acetylglucosamine-1-phosphotransferase is missing, reduced or altered. The enzyme catalyses the first step in the mannose 6-phosphate (M6P) modification of lysosome-destined proteins, which are recognized in the trans-Golgi network (TGN) or at the cell surface by M6P receptors (MPRs) and routed to lysosomes. The defects in mucolipidosis II and IIIA were recently pinpointed to the gene encoding the 
and ß subunits of the enzyme (Tiede et al., 2005; Kudo et al., 2006), and that in mucolipidosis IIIC to the gene for the 
subunit of the complex (Raas-Rothschild et al., 2000; Raas-Rothschild et al. 2004). Whereas the above disorders affect the sorting signal on the cargo, proteins acting as cargo receptors are defective in a bleeding syndrome, combined deficiency of coagulation factors V and VIII. In this, the inclusion of the two coagulation factors into ER-Golgi carriers, and thus their secretion, is hampered by defects in ERGIC-53, a mannose-binding lectin that executes a cargo-sorting function in ER-to-Golgi trafficking (Nichols et al., 1998), or its binding partner, multiple coagulation factor deficiency protein 2 (MCFD2) (Zhang et al., 2003; Zhang et al., 2006). The patients have normal plasma concentrations of other proteins, which suggests that the Ca2+-dependent ERGIC-53-MCFD2 complex has a specific function in sorting of a subgroup of glycoproteins that are transported out of the ER (Zhang et al., 2005). Note that, by analogy with the above examples, one could also include in this category defects in cell surface receptors or adaptor proteins involved in the endocytosis of specific ligands - for example, LDL receptors in familial hypercholesterolemia (FH), which leads to impaired cellular LDL uptake and dramatically increased serum LDL-cholesterol levels. However, owing to space limitations we do not discuss these disorders here.
Arf/Sar GTPases
Small Sar GTPases play central roles in COPII coat assembly and cargo selection at ER exit sites, and the related ARF GTPases function in the recruitment of COPI coats and clathrin/adaptor protein complexes at the Golgi, endosomes and plasma membrane (reviewed by Bonifacino and Glick, 2004; Behnia and Munro, 2005; D'Souza-Schorey and Chavrier, 2006). A striking example of a cargo-inclusion defect due to disturbed coat assembly is provided by chylomicron retention disease (CMRD) and related severe disorders of fat malabsorption. In these disorders, enterocytes fail to secrete lipids derived from the diet into the circulation in the form of chylomicrons, owing to mutations in the gene encoding Sar1b (Jones et al., 2003). The most common genetic defects in the CMRD families are missense mutations that affect residues in the highly conserved guanine-nucleotide-binding motifs of Sar1b. The enterocytes of CMRD patients display chylomicron-like particles in dilated and vesiculated channels of the smooth ER and in huge membrane-bound compartments. Studies by Siddiqi et al. suggest that chylomicrons are included into large ER-to-Golgi carriers ranging in diameter from 350 nm to 500 nm (pre-chylomicron transport vesicles) distinct from the COPII-coated vesicles formed at conventional ER exit sites (Siddiqi et al., 2003). Even though it is not definitely established that chylomicrons leave the ER in COPII-coated carriers, GTP binding and/or hydrolysis by Sar1b seems to play an essential role in chylomicron transport from the ER to the Golgi (reviewed by Shoulders et al., 2004). The fact that Sar1b defects lead to a phenotype restricted to chylomicron secretion and fail to cause global secretory defects is presumably due to the presence of a fully functional Sar1a isoform, which enables near-normal function of the secretory pathway in the majority of the patients' cells. The Sar1b isoform probably interacts with specific ER subdomains employed in the sorting and transport of nascent chylomicrons.
Recently, cranio-lenticulo-sutural dysplasia (CLSD), a disease characterized by facial dysmorphisms and skeletal defects, was shown to result from a defect in the COPII coat subunit SEC23A (Boyadjiev et al., 2006). This protein functions in the same transport step as Sar1, cargo export from the ER, and acts as a GTPase-activating protein (GAP) for Sar1 (Barlowe et al., 1994; Antonny and Schekman, 2001; Bonifacino and Glick, 2004). Consistent with an ER export defect, gross dilatation of the ER was observed in patient fibroblasts (Boyadjiev et al., 2006). Furthermore, Lang et al. showed in zebrafish crusher mutant chondrocytes with an orthologous sec23a defect that proteins accumulate in a distended ER, which results in a severe reduction in cartilage extracellular matrix deposits (Lang et al., 2006). The dysfunction in CLSD resembles that in CMRD, displaying an ER export defect that results in limited disease symptoms in specific cell types. As in the case of Sar1, humans have two paralogous SEC23 genes, of which one is apparently sufficient to carry out a minimal essential ER export function.
Another disorder caused by a defect in small GTPases responsible for coat recruitment is periventricular heterotopia with microcephaly, a syndrome characterized by severe developmental defects of the central nervous system (CNS). Here, the defect has been pinpointed to a guanine nucleotide exchange factor (GEF) for ARF GTPases, ARFGEF2 (Sheen et al., 2004). This protein facilitates GDP-GTP exchange on the GTPase, a process associated with membrane attachment and activation of its coat-recruitment function. ARFGEF2 has been implicated in both ER-to-Golgi and post-Golgi transport; a specific role has been suggested for it in the transport of -aminobutyric acid (GABA) type-A receptor (Charych et al., 2004) and the actin-binding protein filamin A (Lu et al., 2006). Furthermore, ARFGEF2 interacts with Exo70, a protein involved in late exocytic events (Xu et al., 2005). Inhibition of ARFGEF2 prevents the Golgi-to-cell-surface transport of molecules such as E-cadherin and ß-catenin, which suggests that disturbance of vesicle transport through the secretory pathway causes the defects in neuronal proliferation and migration observed in patients (Sheen et al., 2004). In periventricular heterotopia, the major symptoms occur in the CNS, and global secretory defects are not observed. This is probably again because mammalian cells have a number of ARFGEFs (reviewed by Mouratou et al., 2005), and a defect in one only has limited functional consequences.
Membrane lipids
During the past few years, an important role of specific membrane lipids in the recruitment of coat complexes has emerged. A lipid class with major impact on membrane trafficking is the phosphoinositides (PI). The majority of PI are constitutively present in cells and are generally found only on a small subset of organelles; PtsIns(3,4)P2 and PtdIns(3,4,5)P3 are second messengers synthesized in response to external signals (reviewed by Downes et al., 2005; Halstead et al., 2005). PtdIns(4,5)P2 has several pivotal functions in the cell:(1) it serves as substrate for powerful signal-generating enzymes, PI-phospholipase C and type I PI 3-kinases; (2) it is a crucial regulator of the actin cytoskeleton; and (3) it plays a central role in clathrin-mediated endocytosis by recruiting a number of accessory proteins, such as the adapter protein (AP) AP-2, epsin, AP180 and dynamin.
In Lowe oculocerebrorenal syndrome, a protein called OCRL1, a polyphosphoinositide 5-phosphatase, is defective (Attree et al., 1992; Zhang et al., 1995; Suchy et al., 1995). This leads to cellular accumulation of PtdIns(4,5)P2, which induces aberrations in both membrane trafficking and the actin cytoskeleton. OCRL1 localizes to early endosomes and the TGN and is enriched in clathrin-coated transport intermediates. OCRL1 can interact directly with clathrin heavy chain and promote clathrin assembly in vitro (Ungewickell et al., 2004; Choudhury et al., 2005). Furthermore, recent evidence suggests that Rab GTPases regulate both the phosphatase activity and membrane targeting of OCRL1 (Hyvola et al., 2006). Depletion of OCRL1 induces redistribution of the cation-independent MPR to early endosomes, which suggests it has a function in transport from endosomes to the TGN, probably in the recruitment/regulation of trafficking machinery on the endosome membranes (Choudhury et al., 2005). Thus, a defect in transport between endosomes and the TGN, which is consistent with the abnormal secretion of lysosomal hydrolases observed in patients with Lowe syndrome, is likely to contribute to the pathology of the disease.
Hermansky-Pudlak syndrome
Another interesting group of disorders that exhibit defects in the generation of transport intermediates is Hermansky-Pudlak syndrome (HPS), a cluster of diseases characterized by defective biogenesis of lysosome-related organelles (reviewed by Wei, 2006). In HPS2, the disease-causing mutations are in a gene encoding the ß1 subunit of AP-3 (Dell'Angelica et al., 1999). In HPS type 1 and types 3-8, the defects have been pinpointed to subunits of three distinct protein assemblies: biogenesis of lysosome-related organelles complex (BLOC) 1, BLOC2 and BLOC3 (reviewed by Di Pietro and Dell'Angelica, 2005; Gautam et al., 2006) (see Fig. 1). In addition, the mouse models for HPS include animals with mutations in the Sec1-Munc18 protein VPS33A, the small GTPase Rab38, the AP-3
subunit, Rab geranylgeranyl-transferase (RGGT) and several additional components of the BLOC1 complex.
|
), and evidence suggests the complex functions in the transport of integral membrane proteins to late endocytic compartments (reviewed by Robinson and Bonifacino, 2001; Ohno, 2006). In melanocytes, AP-3 is required for the transport of tyrosinase to maturing melanosomes (Huizing et al., 2001). It also appears to play a role in the movement of lytic granules of NK cells and cytotoxic T-lymphocytes (CTLs); the granules in CTLs from HPS2 patients are enlarged and fail to move towards the microtubule-organizing center upon stimulation (Clark et al., 2003). Therefore, AP-3 could participate in the trafficking and correct localization of proteins that attach lytic granules to microtubules.
Our understanding of the cellular functions of the BLOC complexes is limited; they were assumed to function in the biogenesis of lysosome-related organelles. However, there is also experimental evidence for their involvement in LAMP-3 and tyrosinase-related protein-1 trafficking in melanocytes, as well as in the perinuclear clustering of late endocytic compartments in fibroblasts (Boissy et al., 1998; Nazarian et al., 2003; Huizing et al., 2004). The cell biological consequences of the genetically heterogeneous group of HPS disorders are strikingly similar: the same group of specialized lysosome-related organelles (melanosomes, platelet-dense granules, lamellar bodies of type II alveolar epithelial cells, T-lymphocyte lytic granules) is affected by defects in a large number of different protein components. Therefore, HPS and its mouse models have provided valuable functional clues and a toolbox of proteins the detailed analysis of which will facilitate comprehensive understanding of the biogenesis of these organelles.
Dynamins
Dynamins are large GTPases that were first characterized as mediators of clathrin-coated vesicle fission from the plasma membrane (reviewed by Danino and Hinshaw, 2001). Defects in the gene encoding dynamin 2, a ubiquitously expressed dynamin variant, cause two inherited disorders: centronuclear myopathy (Bitoun et al., 2005) and the dominant, intermediate B form of Charcot-Marie-Tooth disease (CMTDIB) (Züchner et al., 2005). Dynamin 2 has been implicated in several cellular functions, including clathrin-dependent endocytosis (Elhamdani et al., 2006), vesicle formation at the TGN (Cao et al., 2005; Kessels et al., 2006), lipid-raft internalization (del Pozo et al., 2005), actin assembly (Schafer et al., 2002; Gomez et al., 2005), and centrosome cohesion (Thompson et al., 2004). Dynamin 2 is expressed in the peripheral nervous system and in the spinal cord, which is relevant for the pathology of Charcot-Marie-Tooth disease (Züchner et al., 2005). In centronuclear myopathy, most of the cellular manifestations, such as centrally located nuclei and a radial arrangement of sarcoplasmic strands around nuclei in extrafusal muscle fibers, may be related to a defect in centrosome function; dynamin 2 has been shown to bind -tubulin at the centrosome and to participate in the cohesion of centrosomes and organization of the microtubule cytoskeleton (Thompson et al., 2004). Centronuclear myopathy also involves mild axonal defects in peripheral nerves (Fischer et al., 2006) and, in CMTDIB, the major pathology involves axonal degeneration in the peripheral nervous system (reviewed by Niemann et al., 2006). These neurological defects may be due to disorganization of the microtubule network, which plays a central role in axonal transport, to impaired transport vesicle formation or both. Alternatively, they may reflect defects in glia or other supportive cells, in which dynamin 2 might be the only major dynamin expressed.
|
Disorders that disturb the motility of transport carriers along cytoskeletal tracks |
|---|
|
TopSummaryIntroductionDefects of the machinery...Disorders that disturb the...Defects in the tethering,...Conclusions and future...References |
|---|
).
Microtubule-based transport
The major motor driving microtubule minus-end-directed movement consists of cytoplasmic dynein and the accessory multiprotein complex dynactin, which increases the processivity of dynein and links cargo to both microtubules and dynein (Schroer, 2004). p150Glued is a central component of dynactin, and point mutations in the DCTN1 gene encoding this protein have been discovered in neurodegenerative diseases. A G59S point mutation causes lower motor neuron disease (Puls et al., 2003). Furthermore, a subset of patients suffering from amyotrophic lateral sclerosis (ALS) 1 also carry point mutations in DCTN1 (Munch et al., 2004; Munch et al., 2005). Detailed analysis of p150Glued G59S revealed that the mutant protein shows reduced affinity for microtubules and is prone to aggregate, which leads to increased cell death in a motor neuron cell line (Levy et al., 2006). The mutation thus causes both a loss of dynein/dynactin function and a toxic effect. Similar effects are found in mice that have missense mutations in the dynein heavy chain or overexpress the dynactin component dynamitin. The resulting defects in dynein-dynactin complexes inhibit retrograde axonal transport (LaMonte et al., 2002; Hafezparast et al., 2003). Interestingly, a dynein mutation can rescue axonal transport in an ALS mouse model caused by a mutation in SOD1 (which encodes superoxide dismutase 1), another gene defective in many human ALS families (Kieran et al., 2005). These findings lend support to the notion that defects in axonal transport are a major cause of neuronal degeneration in ALS and lower motor neuron disease.
|
; Houlden et al., 2004). Rab7 regulates recruitment of dynein/dynactin to endocytic compartments and trafficking in the late endocytic pathway (Press et al., 1998; Jordens et al., 2001; Cantalupo et al., 2001). Importantly, Saxena et al. demonstrated that Rab7 controls the trafficking and neuritogenic signaling of the nerve growth factor (NGF) receptor TrkA, suggesting that Rab7 defects may contribute to neurodegeneration by affecting the transport of neurotrophins or their receptors (Saxena et al., 2005). Another type of Charcot-Marie-Tooth disease, type 2A (CMT2A), is due to a loss-of-function mutation in the motor domain of the plus-end-directed microtubule motor KIF1Bß (Zhao et al., 2001). Studies of heterozygous Kif1B+/- mice revealed that reducing the gene dosage leads to impaired anterograde axonal transport of synaptic vesicle precursors. This reinforces the idea that disturbed axonal transport is a major problem in CMT2A.
Actin-based transport
Defects in actin-based motility have been identified as the cause of Griscelli syndrome (GS), a group of disorders characterized by pigmentation defects (GS1, GS2, GS3), neurological symptoms (GS1), or disturbances of the immunological system (GS2) (see Fig. 2 and Table 1). The disease-causing mutations affect the motor protein myosin 5a (GS1 and GS3) (Pastural et al., 1997; Ménasché et al., 2003), the small GTPase Rab27a (GS2) (Ménasché et al., 2000; Anikster et al., 2002) or a protein called melanophilin or Slac-2 (GS3) (Ménasché et al., 2003). Myosin 5a is essential for the tethering and local movement of melanosomes at the distal actin-rich regions of the melanocyte (Wu et al., 1998 and Fig. 2A). When this mechanism is disturbed, melanosomes accumulate in the central cytoplasm, where they undergo bidirectional movement along microtubules. Rab27a acts as a pivotal component of the myosin 5a receptor on melanosomes (Bahadoran et al., 2001; Wu et al., 2002). The GTPase does not bind myosin 5a directly; the interaction is mediated by melanophilin (Strom et al., 2002; Fukuda et al., 2002).
Rab27a is expressed in cytotoxic T-lymphocytes, and a Rab27a mutation in the ashen mouse model leads to a defect in the docking/fusion of lytic granules at the immunological synapse (Stinchcombe et al., 2001), which provides one plausible explanation for the immune deficiency in GS2. Barral et al. have suggested that Rab27b and Rab27a are functionally redundant and that the pathogenesis of GS2 is determined by the relative expression levels of Rab27a and Rab27b in specialized cell types (Barral et al., 2002). The Rab27a defect in GS2 is connected to that in familial hemophagocytic lymphohistiocytosis (FHL) type 3 (see below). The Munc13-4 protein defective in FHL3 is an effector of Rab27a and plays an essential role in the secretion of lysosomes and cytolytic granules (Feldmann et al., 2003; Neeft et al., 2005) (Fig. 2B).
The mechanisms underlying the neurological deficits in GS1 are not well understood. However, there is evidence for a role of myosin 5a in synaptic function: Libby et al. demonstrated that photoreceptor synapses in neurologically affected myosin-Va-mutant mice have both anatomical abnormalities and display aberrant synaptic activity (Libby et al., 2004).
|
Defects in the tethering, docking and fusion of vesicles at the target membrane |
|---|
|
TopSummaryIntroductionDefects of the machinery...Disorders that disturb the...Defects in the tethering,...Conclusions and future...References |
|---|
-helical proteins, which are typically recruited to the transport vesicle and target membranes by Rab GTPases (reviewed by Zerial and McBride, 2001; Whyte and Munro, 2002; Grosshans et al., 2006). Tethering progresses to more stable docking, after which fusion of the membrane bilayers occurs. Families of soluble N-ethylmaleimide sensitive factor attachment protein receptors (SNAREs) form the core of the machineries acting at this final stage of trafficking. SNAREs are present on vesicle and target membranes and form complexes thought to drive membrane fusion (reviewed by Rothman, 2002; Ungermann and Langosh, 2005; Jahn and Scheller, 2006). The function of SNAREs is controlled by a multitude of accessory factors, the number of which is exceptionally large in the synaptic vesicle and other Ca2+-regulated fusion events (Gerst, 2003; Giraudo et al., 2006).
SNAREs and associated proteins
The first disease-causing mutations in SNARE proteins were discovered in 2005. A deletion in the gene encoding SNAP-29 was found to cause the neurocutaneous CEDNIK syndrome (Sprecher et al., 2005). Analysis of patient skin biopsies revealed abnormalities in the maturation of lamellar granules in the epidermis, as well as mislocation of epidermal glucosylceramide lipids and proteases, which contribute to the formation of the skin barrier and mediate desquamation, respectively. CEDNIK patients also display severe developmental abnormalities in the nervous system. SNAP-29 has been implicated as a generic SNARE protein that inhibits disassembly of SNARE complexes and modulates synaptic transmission (Su et al., 2001; Pan et al., 2005). The exact mechanisms through which the SNAP-29 defect induces the CEDNIK pathology are only partially understood, but the clinical findings, together with what we know about SNAP-29 from cell models, are consistent with a defect in membrane trafficking due to disturbance of the SNARE machinery.
The second SNARE defect identified, familial hemophagocytic lymphohistiocytosis (FHL), is caused by mutations in either syntaxin 11 (FHL type 4) (zur Stadt et al., 2005) or Munc13-4 (FHL type 3) (Feldmann et al., 2003), a Rab27a effector involved in mast cell degranulation (Neeft et al., 2005), secretion of cytolytic granules by CTLs (Feldmann et al., 2003), and secretion of dense core granules by platelets (Shirakawa et al., 2004). Although the functions of Rab27a and Munc13-4 can be linked in a relatively straightforward fashion to defects in cytolytic activity in FHL3 patients (see above), the mechanisms by which syntaxin 11 mutations result in the immunological symptoms in FHL4 are enigmatic. The function of syntaxin 11 has not been investigated in great detail. It colocalizes with MPR on late endosomes and the TGN, and is thought to regulate transport between these compartments (Valdez et al., 1999).
Mutations in a SNARE-interacting protein of the Sec1-Munc18 (SM) protein family, VPS33B, cause arthrogryposis-renal dysfunction-cholestasis (ARC) or incomplete ARC syndromes (Gissen et al., 2004; Bull et al., 2006). VPS33B is an orthologue of Saccharomyces cerevisiae Vps33p, which is involved in the biogenesis and function of the yeast vacuole (Peterson and Emr, 2001). However, the function of mammalian VPS33B has not been studied in detail. The cellular ARC phenotypes include abnormal distribution of plasma membrane proteins (Gissen et al., 2004) as well as platelet and megakaryocyte -granule deficiency (Lo et al., 2005). Furthermore, VPS33B overexpression induces clustering of late endosomes/lysosomes (Gissen et al., 2004; Gissen et al., 2005), indicating that VPS33B is involved in late endosomal membrane dynamics. Together with the clinical features of ARC, these findings are consistent with abnormalities of vesicle transport in the kidney, liver, nervous system and platelets being the underlying cause of ARC pathology.
Accessory factors for Rab GTPases
Genetic disorders caused by mutations in the factors that regulate Rab GTPases include choroideremia (CHM), tuberous sclerosis (TS), and X-linked non-specific mental retardation (MRX). The choroideremia defect has been pinpointed to Rab escort protein 1 (REP1) and was the first Rab-related defect discovered in a human disease (Cremers et al., 1990; Merry et al., 1992; Seabra et al., 1992; Seabra et al., 1993). REP1 acts as a cofactor in the geranyl-geranyl modification of cysteine residues in the C-terminal region of Rab GTPases, a process necessary for Rab membrane association. The CHM pathology results from degeneration of choroid and retinal photoreceptor cell layers (reviewed by Seabra et al., 2002). Even though REP1 represents a very fundamental part of the trafficking machinery, CHM cells retain the ability to process Rabs in a practically normal fashion owing to the presence of another REP isoform, REP2 (Cremers et al., 1994). This provides a plausible explanation for the limited nature of the CHM phenotype. Rab27 is prenylated more efficiently by REP1 than REP2 (Seabra et al., 1995) and expressed in the retinal cell layers that degenerate earliest in CHM; this suggests that Rab27 is the REP1 target critical for CHM pathology. However, the absence of pigmentation and immune system defects characteristic of GS2 patients suggests that the REP1 defect does not severely inhibit Rab27a function in all tissues. Notably, Rak et al. found that Rab27a has a relatively low affinity for both REP isoforms and thus competes poorly with other Rabs, which results in impaired prenylation under conditions in which the overall REP activity is low, such as in CHM (Rak et al., 2004).
The TSC2 gene is mutated in a subset of patients with TS, a disease characterized by tissue hamartomata and tumors (Kumar et al., 1995). The protein, tuberin, is a GAP for the Ras relative Rap1 (Wienecke et al., 1995) and for Rab5, a regulator of early endocytic functions (Xiao et al., 1997). Cells lacking tuberin were reported to possess minimal Rab5 GAP activity and display enhanced fluid-phase endocytosis (Xiao et al., 1997). Tuberin defects may thus cause disturbances of endocytic pathway function and mis-sorting of internalized cargo that would normally be degraded in lysosomes. Such disturbances may be connected with the formation of intracellular inclusions and, eventually, hamartomata.
A further accessory factor for Rab GTPases, Rab GDP dissociation inhibitor (RabGDI), is defective in MRX (D'Adamo et al., 1998; Bienvenu et al., 1998). Deletion of the corresponding mouse gene, Gdi1, results in defective short-term memory, lowers aggression and alters social behavior. Thus, both in mouse and in humans, the defect spares most CNS functions and preferentially impairs only a few forebrain functions (D'Adamo et al., 2002). RabGDI recycles GDP-bound Rabs via the cytosol and allows their specific re-insertion in the appropriate organelle membranes (reviewed by Seabra and Wasmeier, 2004; Pfeffer and Aivazian, 2004). As in CHM, inactivation of a central component of the trafficking machinery results in a relatively subtle and highly limited phenotype in MRX. In mammals, there are two RabGDI isoforms, and most of the functions of GDI can obviously be executed by the second isoform, GDIß. The mental retardation phenotype in MRX could result from minor disturbances in vesicle transport that lead to subtle abnormalities in CNS development.
|
Conclusions and future perspectives |
|---|
|
TopSummaryIntroductionDefects of the machinery...Disorders that disturb the...Defects in the tethering,...Conclusions and future...References |
|---|
). On the other hand, the predominance of neurological symptoms reflects the highly active membrane transport functions of the nervous system. Generation and renewal of synaptic vesicles at the nerve termini require efficient and specialized membrane trafficking (reviewed by Südhof, 2004; Kavalali, 2006). The dimensions of neurites, especially the axon, set a requirement for efficient long-range transport via microtubules (Guzik and Goldstein, 2004; Hirokawa and Takemura, 2005). Furthermore, myelination necessitates efficient and specialized membrane trafficking in glial cells (Larocca and Rodriquez-Gabin, 2002). Second, in several cases - such as CMRD, CLSD, choroideremia, MRX, and periventricular heterotopia with microcephaly - defects in a component that represents a fundamental part of the trafficking machinery fail to cause global transport defects but result in symptoms limited to specific cell types and transport events. This is most easily explained by the redundancy of the trafficking machinery: proteins related to those mutated can compensate for the defects in the majority of cells, and symptoms only arise when a given process is dependent on one specific isoform (e.g. because of strict substrate specificity or limits set by the expression level).
Third, in groups of closely related diseases such as HPS and GS syndromes, efforts to identify the underlying gene defects have revealed groups of gene mutations which lead to similar phenotypic consequences. New trafficking components that are functionally linked have thus been discovered. In the case of GS, disease gene identification has already revealed interactions between Rab27a, melanophilin and myosin 5a, and uncovered a major mechanism by which the subcellular distribution of melanosomes is regulated (Fig. 2A). In the case of HPS, the number of new proteins identified is exceptionally large (Fig. 1), and detailed elucidation of the functions of these components will, as for GS, greatly increase our understanding of the protein-protein interaction networks and molecular mechanisms operating in the biogenesis of lysosome-related organelles.
The ongoing study of the molecular mechanisms underlying the pathology of vesicle transport diseases employs modern gene identification approaches and bioinformatics, detailed phenotypic analysis of patients and cells derived from them, as well as animal models. This work is essential for bringing the molecular details of membrane trafficking into the larger context of mammalian physiology and developmental biology. Furthermore, these efforts will in the future provide tools for developing novel therapeutic approaches. With improving gene transfer technologies, it will in some cases be possible to treat membrane trafficking diseases by providing the subject with a normal version of the mutated gene (Anand et al., 2003; Bizario et al., 2004). Furthermore, the developing stem cell therapy approaches provide good prospects for the treatment of neurological disorders, for instance (Lindvall and Kokaia, 2006). Detailed understanding of the molecular context in which the affected gene product functions should enable the development of intervention strategies based on bypassing the defective step. It may even be possible to apply a suppressor strategy in which manipulation of the activity of another gene product in the pathway compensates for the defect.
|
Acknowledgments |
|---|
|
References |
|---|
|
TopSummaryIntroductionDefects of the machinery...Disorders that disturb the...Defects in the tethering,...Conclusions and future...References |
|---|
Anand, V., Barral, D. C., Zeng, Y., Brunsmann, F., Maguire, A. M., Seabra, M. C. and Bennett, J. (2003). Gene therapy for choroideremia: in vitro rescue mediated by recombinant adenovirus. Vision. Res. 43, 919-926.[CrossRef][Medline]
Anikster, Y., Huizing, M., Anderson, P. D., Fitzpatrick, D. L., Klar, A., Gross-Kieselstein, E., Berkun, Y., Shazberg, G., Gahl, W. A. and Hurvitz, H. (2002). Evidence that Griscelli syndrome with neurological involvement is caused by mutations in RAB27A, not MYO5A. Am. J. Hum. Genet. 71, 407-414.[CrossRef][Medline]
Antonny, B. and Schekman, R. (2001). ER export: public transportation by the COPII coach. Curr. Opin. Cell Biol. 13, 438-443.[CrossRef][Medline]
Attree, O., Olivos, I. M., Okabe, I., Bailey, L. C., Nelson, D. L., Lewis, R. A., McInnes, R. R. and Nussbaum, R. L. (1992). The Lowe's oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase. Nature 358, 239-242.[CrossRef][Medline]
Baetz, K., Isaaz, S. and Griffiths, G. M. (1995). Loss of cytotoxic T lymphocyte function in Chediak-Higashi syndrome arises from a secretory defect that prevents lytic granule exocytosis. J. Immunol. 154, 6122-6131.[Abstract]
Bahadoran, P., Aberdam, E., Mantoux, F., Busca, R., Bille, K., Yalman, N., de Saint-Basile, G., Casaroli-Marano, R., Ortonne, J. P. and Ballotti, R. (2001). Rab27a: A key to melanosome transport in human melanocytes. J. Cell Biol. 152, 843-850.
Barbosa, M. D., Nguyen, Q. A., Tchernev, V. T., Ashley, J. A., Detter, J. C., Blaydes, S. M., Brandt, S. J., Chotai, D., Hodgman, C., Solari, R. C. et al. (1996). Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature 382, 262-265.[CrossRef][Medline]
Bard, F. and Malhotra, V. (2006). The formation of TGN-to-plasma-membrane transport carriers. Annu. Rev. Cell. Dev. Biol. 22, 439-455.[CrossRef][Medline]
Barlowe, C., Orci, L., Yeung, T., Hosobuchi, M., Hamamoto, S., Salama, N., Rexach, M. F., Ravazzola, M., Amherdt, M. and Schekman, R. (1994). COPII: a membrane coat formed by Sec proteins that drive vesicle budding from the endoplasmic reticulum. Cell 77, 895-907.[CrossRef][Medline]
Barral, D. C., Ramalho, J. S., Anders, R., Hume, A. N., Knapton, H. J., Tolmachova, T., Collinson, L. M., Goulding, D., Authi, K. S. and Seabra, M. C. (2002). Functional redundancy of Rab27 proteins and the pathogenesis of Griscelli syndrome. J. Clin. Invest. 110, 247-257.[CrossRef][Medline]
Barrowman, J., Sacher, M. and Ferro-Novick, S. (2000). TRAPP stably associates with the Golgi and is required for vesicle docking. EMBO. J. 19, 862-869.[CrossRef][Medline]
Behnia, R. and Munro, S. (2005). Organelle identity and the signposts for membrane traffic. Nature 438, 597-604.[CrossRef][Medline]
Bienvenu, T., des Portes, V., Saint Martin, A., McDonell, N., Billuart, P., Carrie, A., Vinet, M. C., Couvert, P., Toniolo, D., Ropers, H. H. et al. (1998). Non-specific X-linked semidominant mental retardation by mutations in a Rab GDP-dissociation inhibitor. Hum. Mol. Genet. 7, 1311-1315.
Bitoun, M., Maugenre, S., Jeannet, P. Y., Lacene, E., Ferrer, X., Laforet, P., Martin, J. J., Laporte, J., Lochmuller, H., Beggs, A. H. et al. (2005). Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat. Genet. 37, 1207-1209.[CrossRef][Medline]
Bizario, J. C., Feldmann, J., Castro, F. A., Menasche, G., Jacob, C. M., Cristofani, L., Casella, E. B., Voltarelli, J. C., de Saint-Basile, G. and Espreafico, E. M. (2004). Griscelli syndrome: characterization of a new mutation and rescue of T-cytotoxic activity by retroviral transfer of RAB27A gene. J. Clin. Immunol. 24, 397-410.[CrossRef][Medline]
Blair, M. A., Ma, S. and Hedera, P. (2006). Mutation in KIF5A can also cause adult-onset hereditary spastic paraplegia. Neurogenetics 7, 47-50.[CrossRef][Medline]
Boissy, R. E., Zhao, Y. and Gahl, W. A. (1998). Altered protein localization in melanocytes from Hermansky-Pudlak syndrome: support for the role of the HPS gene product in intracellular trafficking. Lab. Invest. 78, 1037-1048.[Medline]
Bonifacino, J. S. and Glick, B. S. (2004). The mechanisms of vesicle budding and fusion. Cell 116, 153-166.[CrossRef][Medline]
Bonifacino, J. S. and Rojas, R. (2006). Retrograde transport from endosomes to the trans-Golgi network. Nat. Rev. Mol. Cell. Biol. 7, 568-579.[CrossRef][Medline]
Boyadjiev, S. A., Fromme, J. C., Ben, J., Chong, S. S., Nauta, C., Hur, D. J., Zhang, G., Hamamoto, S., Schekman, R., Ravazzola, M. et al. (2006). Cranio-lenticulosutural dysplasia is caused by a SEC23A mutation leading to abnormal endoplasmic-reticulum-to-Golgi trafficking. Nat. Genet. 38, 1192-1197.[CrossRef][Medline]
Brickner, J. H. and Fuller, R. S. (1997). SOI1 encodes a novel, conserved protein that promotes TGN-endosomal cycling of Kex2p and other membrane proteins by modulating the function of two TGN localization signals. J. Cell Biol. 139, 23-36.
Bull, L. N., Mahmoodi, V., Baker, A. J., Jones, R., Strautnieks, S. S., Thompson, R. J. and Knisely, A. S. (2006). VPS33B mutation with ichthyosis, cholestasis, and renal dysfunction but without arthrogryposis: incomplete ARC syndrome phenotype. J. Pediatr. 148, 269-271.[CrossRef][Medline]
Cantalupo, G., Alifano, P., Roberti, V., Bruni, C. B. and Bucci, C. (2001). Rab-interacting lysosomal protein (RILP): the Rab7 effector required for transport to lysosomes. EMBO J. 20, 683-693.[CrossRef][Medline]
Cao, H., Weller, S., Orth, J. D., Chen, J., Huang, B., Chen, J. L., Stamnes, M. and McNiven, M. A. (2005). Actin and Arf1-dependent recruitment of a cortactin-dynamin complex to the Golgi regulates post-Golgi transport. Nat. Cell Biol. 7, 483-492.[CrossRef][Medline]
Charych, E. I., Yu, W., Miralles, C. P., Serwanski, D. R., Li, X., Rubio, M. and De Blas, A. L. (2004). The brefeldin A-inhibited GDP/GTP exchange factor 2, a protein involved in vesicular trafficking, interacts with the beta subunits of the GABA receptors. J. Neurochem. 90, 173-189.[CrossRef][Medline]
Choudhury, R., Diao, A., Zhang, F., Eisenberg, E., Saint-Pol, A., Williams, C., Konstantakopoulos, A., Lucocq, J., Johannes, L., Rabouille, C. et al. (2005). Lowe syndrome protein OCRL1 interacts with clathrin and regulates protein trafficking between endosomes and the trans-Golgi network. Mol. Biol. Cell 16, 3467-3479.
Clark, R. H., Stinchcombe, J. C., Day, A., Blott, E., Booth, S., Bossi, G., Hamblin, T., Davies, E. G. and Griffiths, G. M. (2003). Adaptor protein 3-dependent microtubule-mediated movement of lytic granules to the immunological synapse. Nat. Immunol. 4, 1111-1120.[CrossRef][Medline]
Cremers, F. P., van de Pol, D. J., van Kerkhoff, L. P., Wieringa, B. and Ropers, H. H. (1990). Cloning of a gene that is rearranged in patients with choroideraemia. Nature 347, 674-677.[CrossRef][Medline]
Cremers, F. P., Armstrong, S. A., Seabra, M. C., Brown, M. S. and Goldstein, J. L. (1994). REP-2, a Rab escort protein encoded by the choroideremia-like gene. J. Biol. Chem. 269, 2111-2117.
D'Adamo, P., Menegon, A., Lo Nigro, C., Grasso, M., Gulisano, M., Tamanini, F., Bienvenu, T., Gedeon, A. K., Oostra, B., Wu, S. K. et al. (1998). Mutations in GDI1 are responsible for X-linked non-specific mental retardation. Nat. Genet. 19, 134-139.[CrossRef][Medline]
D'Adamo, P., Welzl, H., Papadimitriou, S., Raffaele di Barletta, M., Tiveron, C., Tatangelo, L., Pozzi, L., Chapman, P. F., Knevett, S. G., Ramsay, M. F. et al. (2002). Deletion of the mental retardation gene Gdi1 impairs associative memory and alters social behavior in mice. Hum. Mol. Genet. 11, 2567-2580.
D'Souza-Schorey, C. and Chavrier, P. (2006). ARF proteins: roles in membrane traffic and beyond. Nat. Rev. Mol. Cell Biol. 7, 347-358.[CrossRef][Medline]
Danino, D. and Hinshaw, J. E. (2001). Dynamin family of mechanoenzymes. Curr. Opin. Cell Biol. 13, 454-460.[CrossRef][Medline]
del Pozo, M. A., Balasubramanian, N., Alderson, N. B., Kiosses, W. B., Grande-Garcia, A., Anderson, R. G. and Schwartz, M. A. (2005). Phospho-caveolin-1 mediates integrin-regulated membrane domain internalization. Nat. Cell Biol. 7, 901-908.[CrossRef][Medline]
Dell'Angelica, E. C., Shotelersuk, V., Aguilar, R. C., Gahl, W. A. and Bonifacino, J. S. (1999). Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol. Cell 3, 11-21.[CrossRef][Medline]
Di Pietro, S. M. and Dell'Angelica, E. C. (2005). The cell biology of Hermansky-Pudlak syndrome: recent advances. Traffic 6, 525-533.[CrossRef][Medline]
Dobson-Stone, C., Velayos-Baeza, A., Jansen, A., Andermann, F., Dubeau, F., Robert, F., Summers, A., Lang, A. E., Chouinard, S., Danek, A. et al. (2005). Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. Neurogenetics 6, 151-158.[CrossRef][Medline]
Downes, C. P., Gray, A. and Lucocq, J. M. (2005). Probing phosphoinositide functions in signaling and membrane trafficking. Trends Cell Biol. 15, 259-268.[CrossRef][Medline]
Elhamdani, A., Azizi, F., Solomaha, E., Palfrey, H. C. and Artalejo, C. R. (2006). Two mechanistically distinct forms of endocytosis in adrenal chromaffin cells: Differential effects of SH3 domains and amphiphysin antagonism. FEBS Lett. 580, 3263-3269.[CrossRef][Medline]
Eskelinen, E. L., Tanaka, Y. and Saftig, P. (2003). At the acidic edge: emerging functions for lysosomal membrane proteins. Trends Cell Biol. 13, 137-145.[CrossRef][Medline]
Evans, K. J., Gomes, E. R., Reisenweber, S. M., Gundersen, G. G. and Lauring, B. P. (2005). Linking axonal degeneration to microtubule remodeling by Spastin-mediated microtubule severing. J. Cell Biol. 168, 599-606.
Faigle, W., Raposo, G., Tenza, D., Pinet, V., Vogt, A. B., Kropshofer, H., Fischer, A., de Saint-Basile, G. and Amigorena, S. (1998). Deficient peptide loading and MHC class II endosomal sorting in a human genetic immunodeficiency disease: the Chediak-Higashi syndrome. J. Cell Biol. 141, 1121-1134.
Feldmann, J., Callebaut, I., Raposo, G., Certain, S., Bacq, D., Dumont, C., Lambert, N., Ouachee-Chardin, M., Chedeville, G., Tamary, H. et al. (2003). Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115, 461-473.[CrossRef][Medline]
Fichera, M., Lo Giudice, M., Falco, M., Sturnio, M., Amata, S., Calabrese, O., Bigoni, S., Calzolari, E. and Neri, M. (2004). Evidence of kinesin heavy chain (KIF5A) involvement in pure hereditary spastic paraplegia. Neurology 63, 1108-1110.
Fischer, D., Herasse, M., Bitoun, M., Barragan-Campos, H. M., Chiras, J., Laforet, P., Fardeau, M., Eymard, B., Guicheney, P. and Romero, N. B. (2006). Characterization of the muscle involvement in dynamin 2-related centronuclear myopathy. Brain 129, 1463-1469.
Fukuda, M., Kuroda, T. S. and Mikoshiba, K. (2002). Slac2-a/melanophilin, the missing link between Rab27 and myosin Va: implications of a tripartite protein complex for melanosome transport. J. Biol. Chem. 277, 12432-12436.
Gautam, R., Novak, E. K., Tan, J., Wakamatsu, K., Ito, S. and Swank, R. T. (2006). Interaction of Hermansky-Pudlak Syndrome genes in the regulation of lysosome-related organelles. Traffic 7, 779-792.[CrossRef][Medline]
Gauthier, L. R., Charrin, B. C., Borrell-Pages, M., Dompierre, J. P., Rangone, H., Cordelieres, F. P., De Mey, J., MacDonald, M. E., Lessmann, V., Humbert, S. et al. (2004). Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118, 127-138.[CrossRef][Medline]
Gedeon, A. K., Colley, A., Jamieson, R., Thompson, E. M., Rogers, J., Sillence, D., Tiller, G. E., Mulley, J. C. and Gecz, J. (1999). Identification of the gene (SEDL) causing X-linked spondyloepiphyseal dysplasia tarda. Nat. Genet. 22, 400-404.[Medline]
Gedeon, A. K., Tiller, G. E., Le Merrer, M., Heuertz, S., Tranebjaerg, L., Chitayat, D., Robertson, S., Glass, I. A., Savarirayan, R., Cole, W. G. et al. (2001). The molecular basis of X-linked spondyloepiphyseal dysplasia tarda. Am. J. Hum. Genet. 68, 1386-1397.[CrossRef][Medline]
Gerst, J. E. (2003). SNARE regulators: matchmakers and matchbreakers. Biochim. Biophys. Acta 1641, 99-110.[Medline]
Giraudo, C. G., Eng, W. S., Melia, T. J. and Rothman, J. E. (2006). A Clamping Mechanism Involved in SNARE-Dependent Exocytosis. Science 676-680.
Gissen, P., Johnson, C. A., Morgan, N. V., Stapelbroek, J. M., Forshew, T., Cooper, W. N., McKiernan, P. J., Klomp, L. W., Morris, A. A., Wraith, J. E. et al. (2004). Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat. Genet. 36, 400-404.[CrossRef][Medline]
Gissen, P., Johnson, C. A., Gentle, D., Hurst, L. D., Doherty, A. J., O'Kane, C. J., Kelly, D. A. and Maher, E. R. (2005). Comparative evolutionary analysis of VPS33 homologues: genetic and functional insights. Hum. Mol. Genet. 14, 1261-1270.
Goishi, K., Mizuno, K., Nakanishi, H. and Sasaki, T. (2004). Involvement of Rab27 in antigen-induced histamine release from rat basophilic leukemia 2H3 cells. Biochem. Biophys. Res. Commun. 324, 294-301.[CrossRef][Medline]
Gomez, T. S., Hamann, M. J., McCarney, S., Savoy, D. N., Lubking, C. M., Heldebrant, M. P., Labno, C. M., McKean, D. J., McNiven, M. A., Burkhardt, J. K. et al. (2005). Dynamin 2 regulates T cell activation by controlling actin polymerization at the immunological synapse. Nat. Immunol. 6, 261-270.[CrossRef][Medline]
Grosshans, B. L., Ortiz, D. and Novick, P. (2006). Rabs and their effectors: achieving specificity in membrane traffic. Proc. Natl. Acad. Sci. USA 103, 11821-11827.
Gunawardena, S., Her, L. S., Brusch, R. G., Laymon, R. A., Niesman, I. R., Gordesky-Gold, B., Sintasath, L., Bonini, N. M. and Goldstein, L. S. (2003). Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40, 25-40.[CrossRef][Medline]
Guzik, B. W. and Goldstein, L. S. (2004). Microtubule-dependent transport in neurons: steps towards an understanding of regulation, function and dysfunction. Curr. Opin. Cell Biol. 16, 443-450.[CrossRef][Medline]
Hafezparast, M., Klocke, R., Ruhrberg, C., Marquardt, A., Ahmad-Annuar, A., Bowen, S., Lalli, G., Witherden, A. S., Hummerich, H., Nicholson, S. et al. (2003). Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300, 808-812.
Halstead, J. R., Jalink, K. and Divecha, N. (2005). An emerging role for PtdIns(4,5)P2-mediated signalling in human disease. Trends Pharmacol. Sci. 26, 654-660.[CrossRef][Medline]
Hamamoto, I., Nishimura, Y., Okamoto, T., Aizaki, H., Liu, M., Mori, Y., Abe, T., Suzuki, T., Lai, M. M., Miyamura, T. et al. (2005). Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J. Virol. 79, 13473-13482.
Harjes, P. and Wanker, E. E. (2003). The hunt for huntingtin function: interaction partners tell many different stories. Trends Biochem. Sci. 28, 425-433.[CrossRef][Medline]
Hazan, J., Fonknechten, N., Mavel, D., Paternotte, C., Samson, D., Artiguenave, F., Davoine, C. S., Cruaud, C., Durr, A., Wincker, P. et al. (1999). Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat. Genet. 23, 296-303.[CrossRef][Medline]
Hirokawa, N. and Takemura, R. (2003). Biochemical and molecular characterization of diseases linked to motor proteins. Trends Biochem. Sci. 28, 558-565.[CrossRef][Medline]
Hirokawa, N. and Takemura, R. (2005). Molecular motors and mechanisms of directional transport in neurons. Nat. Rev. Neurosci. 6, 201-214.[CrossRef][Medline]
Houlden, H., King, R. H., Muddle, J. R., Warner, T. T., Reilly, M. M., Orrell, R. W. and Ginsberg, L. (2004). A novel RAB7 mutation associated with ulcero-mutilating neuropathy. Ann. Neurol. 56, 586-590.[CrossRef][Medline]
Huizing, M., Sarangarajan, R., Strovel, E., Zhao, Y., Gahl, W. A. and Boissy, R. E. (2001). AP-3 mediates tyrosinase but not TRP-1 trafficking in human melanocytes. Mol. Biol. Cell 12, 2075-2085.
Huizing, M., Hess, R., Dorward, H., Claassen, D. A., Helip-Wooley, A., Kleta, R., Kaiser-Kupfer, M. I., White, J. G. and Gahl, W. A. (2004). Cellular, molecular and clinical characterization of patients with Hermansky-Pudlak syndrome type 5. Traffic 5, 711-722.[CrossRef][Medline]
Humbert, S., Bryson, E. A., Cordelieres, F. P., Connors, N. C., Datta, S. R., Finkbeiner, S., Greenberg, M. E. and Saudou, F. (2002). The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell 2, 831-837.[CrossRef][Medline]
Huynh, C., Roth, D., Ward, D. M., Kaplan, J. and Andrews, N. W. (2004). Defective lysosomal exocytosis and plasma membrane repair in Chediak-Higashi/beige cells. Proc. Natl. Acad. Sci. USA 101, 16795-16800.
Hyvola, N., Diao, A., McKenzie, E., Skippen, A., Cockcroft, S. and Lowe, M. (2006). Membrane targeting and activation of the Lowe syndrome protein OCRL1 by rab GTPases. EMBO J. 25, 3750-3761.[CrossRef][Medline]
Jahn, R. and Scheller, R. H. (2006). SNAREs - engines for membrane fusion. Nat. Rev. Mol. Cell Biol. 7, 631-643.[CrossRef][Medline]
Jones, B., Jones, E. L., Bonney, S. A., Patel, H. N., Mensenkamp, A. R., Eichenbaum-Voline, S., Rudling, M., Myrdal, U., Annesi, G., Naik, S. et al. (2003). Mutations in a Sar1 GTPase of COPII vesicles are associated with lipid absorption disorders. Nat. Genet. 34, 29-31.[CrossRef][Medline]
Jordens, I., Fernandez-Borja, M., Marsman, M., Dusseljee, S., Janssen, L., Calafat, J., Janssen, H., Wubbolts, R. and Neefjes, J. (2001). The Rab7 effector protein RILP controls lysosomal transport by inducing the recruitment of dynein-dynactin motors. Curr. Biol. 11, 1680-1685.[CrossRef][Medline]
Kanekura, K., Nishimoto, I., Aiso, S. and Matsuoka, M. (2006). Characterization of amyotrophic lateral sclerosis-linked pro56ser mutation of vesicle-associated membrane protein-associated protein B (VAPB/ALS8). J. Biol. Chem. 281, 30223-30233.
Kavalali, E. T. (2006). Synaptic vesicle reuse and its implications. Neuroscientist 12, 57-66.
Kessels, M. M., Dong, J., Leibig, W., Westermann, P. and Qualmann, B. (2006). Complexes of syndapin II with dynamin II promote vesicle formation at the trans-Golgi network. J. Cell Sci. 119, 1504-1516.
Kieran, D., Hafezparast, M., Bohnert, S., Dick, J. R., Martin, J., Schiavo, G., Fisher, E. M. and Greensmith, L. (2005). A mutation in dynein rescues axonal transport defects and extends the life span of ALS mice. J. Cell Biol. 169, 561-567.
Kittler, J. T., Thomas, P., Tretter, V., Bogdanov, Y. D., Haucke, V., Smart, T. G. and Moss, S. J. (2004). Huntingtin-associated protein 1 regulates inhibitory synaptic transmission by modulating gamma-aminobutyric acid type A receptor membrane trafficking. Proc. Natl. Acad. Sci. USA 101, 12736-12741.
Kolehmainen, J., Black, G. C., Saarinen, A., Chandler, K., Clayton-Smith, J., Traskelin, A. L., Perveen, R., Kivitie-Kallio, S., Norio, R., Warburg, M. et al. (2003). Cohen syndrome is caused by mutations in a novel gene, COH1, encoding a transmembrane protein with a presumed role in vesicle-mediated sorting and intracellular protein transport. Am. J. Hum. Genet. 72, 1359-1369.[CrossRef][Medline]
Kudo, M., Brem, M. S. and Canfield, W. M. (2006). Mucolipidosis II (I-cell disease) and mucolipidosis IIIA (classical pseudo-hurler polydystrophy) are caused by mutations in the GlcNAc-phosphotransferase alpha/beta-subunits precursor gene. Am. J. Hum. Genet. 78, 451-463.[CrossRef][Medline]
Kumar, A., Kandt, R. S., Wolpert, C., Roses, A. D., Pericak-Vance, M. A. and Gilbert, J. R. (1995). Mutation analysis of the TSC2 gene in an African-American family. Hum. Mol. Genet. 4, 2295-2298.
LaMonte, B. H., Wallace, K. E., Holloway, B. A., Shelly, S. S., Ascano, J., Tokito, M., Van Winkle, T., Howland, D. S. and Holzbaur, E. L. (2002). Disruption of dynein/dynactin inhibits axonal transport in motor neurons causing late-onset progressive degeneration. Neuron 34, 715-727.[CrossRef][Medline]
Lang, M. R., Lapierre, L. A., Frotscher, M., Goldenring, J. R. and Knapik, E. W. (2006). Secretory COPII coat component Sec23a is essential for craniofacial chondrocyte maturation. Nat. Genet. 38, 1198-1203.[CrossRef][Medline]
Larocca, J. N. and Rodriguez-Gabin, A. G. (2002). Myelin biogenesis: vesicle transport in oligodendrocytes. Neurochem. Res. 27, 1313-1329.[CrossRef][Medline]
Levy, J. R., Sumner, C. J., Caviston, J. P., Tokito, M. K., Ranganathan, S., Ligon, L. A., Wallace, K. E., LaMonte, B. H., Harmison, G. G., Puls, I. et al. (2006). A motor neuron disease-associated mutation in p150Glued perturbs dynactin function and induces protein aggregation. J. Cell Biol. 172, 733-745.
Libby, R. T., Lillo, C., Kitamoto, J., Williams, D. S. and Steel, K. P. (2004). Myosin Va is required for normal photoreceptor synaptic activity. J. Cell Sci. 117, 4509-4515.
Lindvall, O. and Kokaia, Z. (2006). Stem cells for the treatment of neurological disorders. Nature 441, 1094-1096.[CrossRef][Medline]
Lo, B., Li, L., Gissen, P., Christensen, H., McKiernan, P. J., Ye, C., Abdelhaleem, M., Hayes, J. A., Williams, M. D., Chitayat, D. and Kahr, W. H. (2005). Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet alpha-granule biogenesis. Blood 106, 4159-4166.
Lo Giudice, M., Neri, M., Falco, M., Sturnio, M., Calzolari, E., Di Benedetto, D. and Fichera, M. (2006). A missense mutation in the coiled-coil domain of the KIF5A gene and late-onset hereditary spastic paraplegia. Arch. Neurol. 63, 284-287.
Lowe, M. (2005). Structure and function of the Lowe syndrome protein OCRL1. Traffic 6, 711-719.[CrossRef][Medline]
Lu, J., Tiao, G., Folkerth, R., Hecht, J., Walsh, C. and Sheen, V. (2006). Overlapping expression of ARFGEF2 and Filamin A in the neuroependymal lining of the lateral ventricles: insights into the cause of periventricular heterotopia. J. Comp. Neurol. 494, 476-484.[CrossRef][Medline]
Maxfield, F. R. and McGraw, T. E. (2004). Endocytic recycling. Nat. Rev. Mol. Cell Biol. 5, 121-132.[CrossRef][Medline]
McNiven, M. A. and Thompson, H. M. (2006). Vesicle formation at the plasma membrane and trans-Golgi network: the same but different. Science 313, 1591-1594.
McVey Ward, D., Shiflett, S. L. and Kaplan, J. (2002). Chediak-Higashi syndrome: a clinical and molecular view of a rare lysosomal storage disorder. Curr. Mol. Med. 2, 469-477.[CrossRef][Medline]
McVey Ward, D., Shiflett, S. L., Huynh, D., Vaughn, M. B., Prestwich, G. and Kaplan, J. (2003). Use of expression constructs to dissect the functional domains of the CHS/beige protein: identification of multiple phenotypes. Traffic 4, 403-415.[CrossRef][Medline]
Menasche, G., Pastural, E., Feldmann, J., Certain, S., Ersoy, F., Dupuis, S., Wulffraat, N., Bianchi, D., Fischer, A., Le Deist, F. et al. (2000). Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat. Genet. 25, 173-176.[CrossRef][Medline]
Menasche, G., Ho, C. H., Sanal, O., Feldmann, J., Tezcan, I., Ersoy, F., Houdusse, A., Fischer, A. and de Saint Basile, G. (2003). Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). J. Clin. Invest. 112, 450-456.[CrossRef][Medline]
Merry, D. E., Janne, P. A., Landers, J. E., Lewis, R. A. and Nussbaum, R. L. (1992). Isolation of a candidate gene for choroideremia. Proc. Natl. Acad. Sci. USA 89, 2135-2139.
Mouratou, B., Biou, V., Joubert, A., Cohen, J., Shields, D. J., Geldner, N., Jurgens, G., Melancon, P. and Cherfils, J. (2005). The domain architecture of large guanine nucleotide exchange factors for the small GTP-binding protein Arf. BMC Genomics 6, 20.[CrossRef][Medline]
Munch, C., Sedlmeier, R., Meyer, T., Homberg, V., Sperfeld, A. D., Kurt, A., Prudlo, J., Peraus, G., Hanemann, C. O., Stumm, G. et al. (2004). Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS. Neurology 63, 724-726.
Munch, C., Rosenbohm, A., Sperfeld, A. D., Uttner, I., Reske, S., Krause, B. J., Sedlmeier, R., Meyer, T., Hanemann, C. O., Stumm, G. et al. (2005). Heterozygous R1101K mutation of the DCTN1 gene in a family with ALS and FTD. Ann. Neurol. 58, 777-780.[CrossRef][Medline]
Nagle, D. L., Karim, M. A., Woolf, E. A., Holmgren, L., Bork, P., Misumi, D. J., McGrail, S. H., Dussault, B. J., Jr, Perou, C. M., Boissy, R. E. et al. (1996). Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat. Genet. 14, 307-311.[CrossRef][Medline]
Nazarian, R., Falcon-Perez, J. M. and Dell'Angelica, E. C. (2003). Biogenesis of lysosome-related organelles complex 3 (BLOC-3): a complex containing the Hermansky-Pudlak syndrome (HPS) proteins HPS1 and HPS4. Proc. Natl. Acad. Sci. USA 100, 8770-8775.
Neeft, M., Wieffer, M., de Jong, A. S., Negroiu, G., Metz, C. H., van Loon, A., Griffith, J., Krijgsveld, J., Wulffraat, N., Koch, H. et al. (2005). Munc13-4 is an effector of rab27a and controls secretion of lysosomes in hematopoietic cells. Mol. Biol. Cell 16, 731-741.
Nichols, W. C., Seligsohn, U., Zivelin, A., Terry, V. H., Hertel, C. E., Wheatley, M. A., Moussalli, M. J., Hauri, H. P., Ciavarella, N., Kaufman, R. J. et al. (1998). Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 93, 61-70.[CrossRef][Medline]
Niemann, A., Berger, P. and Suter, U. (2006). Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease. Neuromolecular Med. 8, 217-242.[CrossRef][Medline]
Nishimura, A. L., Mitne-Neto, M., Silva, H. C., Richieri-Costa, A., Middleton, S., Cascio, D., Kok, F., Oliveira, J. R., Gillingwater, T., Webb, J. et al. (2004). A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. 75, 822-831.[CrossRef][Medline]
Nishimura, Y., Hayashi, M., Inada, H. and Tanaka, T. (1999). Molecular cloning and characterization of mammalian homologues of vesicle-associated membrane protein-associated (VAMP-associated) proteins. Biochem. Biophys. Res. Commun. 254, 21-26.[CrossRef][Medline]
Nishino, I., Fu, J., Tanji, K., Yamada, T., Shimojo, S., Koori, T., Mora, M., Riggs, J. E., Oh, S. J., Koga, Y. et al. (2000). Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406, 906-910.[CrossRef][Medline]
Ohno, H. (2006). Clathrin-associated adaptor protein complexes. J. Cell Sci. 119, 3719-3721.
Olkkonen, V. M. and Ikonen, E. (2000). Genetic defects of intracellular-membrane transport. N. Engl. J. Med. 343, 1095-1104.
Pan, P. Y., Cai, Q., Lin, L., Lu, P. H., Duan, S. and Sheng, Z. H. (2005). SNAP-29-mediated modulation of synaptic transmission in cultured hippocampal neurons. J. Biol. Chem. 280, 25769-25779.
Pastural, E., Barrat, F. J., Dufourcq-Lagelouse, R., Certain, S., Sanal, O., Jabado, N., Seger, R., Griscelli, C., Fischer, A. and de Saint Basile, G. (1997). Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. Nat. Genet. 16, 289-292.[CrossRef][Medline]
Peden, A. A., Oorschot, V., Hesser, B. A., Austin, C. D., Scheller, R. H. and Klumperman, J. (2004). Localization of the AP-3 adaptor complex defines a novel endosomal exit site for lysosomal membrane proteins. J. Cell Biol. 164, 1065-1076.
Perou, C. M., Leslie, J. D., Green, W., Li, L., Ward, D. M. and Kaplan, J. (1997). The Beige/Chediak-Higashi syndrome gene encodes a widely expressed cytosolic protein. J. Biol. Chem. 272, 29790-29794.
Peterson, M. R. and Emr, S. D. (2001). The class C Vps complex functions at multiple stages of the vacuolar transport pathway. Traffic 2, 476-486.[CrossRef][Medline]
Pfeffer, S. and Aivazian, D. (2004). Targeting Rab GTPases to distinct membrane compartments. Nat. Rev. Mol. Cell Biol. 5, 886-896.[CrossRef][Medline]
Press, B., Feng, Y., Hoflack, B. and Wandinger-Ness, A. (1998). Mutant Rab7 causes the accumulation of cathepsin D and cation-independent mannose 6-phosphate receptor in an early endocytic compartment. J. Cell Biol. 140, 1075-1089.
Puls, I., Jonnakuty, C., LaMonte, B. H., Holzbaur, E. L., Tokito, M., Mann, E., Floeter, M. K., Bidus, K., Drayna, D., Oh, S. J. et al. (2003). Mutant dynactin in motor neuron disease. Nat. Genet. 33, 455-456.[CrossRef][Medline]
Qin, Z. H., Wang, Y., Sapp, E., Cuiffo, B., Wanker, E., Hayden, M. R., Kegel, K. B., Aronin, N. and DiFiglia, M. (2004). Huntingtin bodies sequester vesicle-associated proteins by a polyproline-dependent interaction. J. Neurosci. 24, 269-281.
Raas-Rothschild, A., Cormier-Daire, V., Bao, M., Genin, E., Salomon, R., Brewer, K., Zeigler, M., Mandel, H., Toth, S., Roe, B. et al. (2000). Molecular basis of variant pseudo-hurler polydystrophy (mucolipidosis IIIC). J. Clin. Invest. 105, 673-681.[Medline]
Raas-Rothschild, A., Bargal, R., Goldman, O., Ben-Asher, E., Groener, J. E., Toutain, A., Stemmer, E., Ben-Neriah, Z., Flusser, H., Beemer, F. A. et al. (2004). Genomic organisation of the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTAG) and its mutations in mucolipidosis III. J. Med. Genet. 41, e52.
Rak, A., Pylypenko, O., Niculae, A., Pyatkov, K., Goody, R. S. and Alexandrov, K. (2004). Structure of the Rab7:REP-1 complex: insights into the mechanism of Rab prenylation and choroideremia disease. Cell 117, 749-760.[CrossRef][Medline]
Rampoldi, L., Dobson-Stone, C., Rubio, J. P., Danek, A., Chalmers, R. M., Wood, N. W., Verellen, C., Ferrer, X., Malandrini, A., Fabrizi, G. M. et al. (2001). A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat. Genet. 28, 119-120.[CrossRef][Medline]
Reid, E., Kloos, M., Ashley-Koch, A., Hughes, L., Bevan, S., Svenson, I. K., Graham, F. L., Gaskell, P. C., Dearlove, A., Pericak-Vance, M. A. et al. (2002). A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am. J. Hum. Genet. 71, 1189-1194.[CrossRef][Medline]
Reid, E., Connell, J., Edwards, T. L., Duley, S., Brown, S. E. and Sanderson, C. M. (2005). The hereditary spastic paraplegia protein spastin interacts with the ESCRT-III complex-associated endosomal protein CHMP1B. Hum. Mol. Genet. 14, 19-38.
Robinson, M. S. and Bonifacino, J. S. (2001). Adaptor-related proteins. Curr. Opin. Cell. Biol. 13, 444-453.[CrossRef][Medline]
Rothman, J. E. (2002). Lasker Basic Medical Research Award. The machinery and principles of vesicle transport in the cell. Nat. Med. 8, 1059-1062.[CrossRef][Medline]
Sacher, M., Jiang, Y., Barrowman, J., Scarpa, A., Burston, J., Zhang, L., Schieltz, D., Yates, J. R., 3rd, Abeliovich, H. and Ferro-Novick, S. (1998). TRAPP, a highly conserved novel complex on the cis-Golgi that mediates vesicle docking and fusion. EMBO J. 17, 2494-2503.[CrossRef][Medline]
Sacher, M., Barrowman, J., Wang, W., Horecka, J., Zhang, Y., Pypaert, M. and Ferro-Novick, S. (2001). TRAPP I implicated in the specificity of tethering in ER-to-Golgi transport. Mol. Cell. 7, 433-442.[CrossRef][Medline]
Salinas, S., Carazo-Salas, R. E., Proukakis, C., Cooper, J. M., Weston, A. E., Schiavo, G. and Warner, T. T. (2005). Human spastin has multiple microtubule-related functions. J. Neurochem. 95, 1411-1420.[CrossRef][Medline]
Sands, M. S. and Davidson, B. L. (2006). Gene therapy for lysosomal storage diseases. Mol. Ther. 13, 839-849.[CrossRef][Medline]
Sannerud, R., Saraste, J. and Goud, B. (2003). Retrograde traffic in the biosynthetic-secretory route: pathways and machinery. Curr. Opin. Cell Biol. 15, 438-445.[CrossRef][Medline]
Saxena, S., Bucci, C., Weis, J. and Kruttgen, A. (2005). The small GTPase Rab7 controls the endosomal trafficking and neuritogenic signaling of the nerve growth factor receptor TrkA. J. Neurosci. 25, 10930-10940.
Schafer, D. A., Weed, S. A., Binns, D., Karginov, A. V., Parsons, J. T. and Cooper, J. A. (2002). Dynamin2 and cortactin regulate actin assembly and filament organization. Curr. Biol. 12, 1852-1857.[CrossRef][Medline]
Schroer, T. A. (2004). Dynactin. Annu. Rev. Cell Dev. Biol. 20, 759-779.[CrossRef][Medline]
Seabra, M. C., Mules, E. H. and Hume, A. N. (2002). Rab GTPases, intracellular traffic and disease. Trends Mol. Med. 8, 23-30.[CrossRef][Medline]
Seabra, M. C. and Wasmeier, C. (2004). Controlling the location and activation of Rab GTPases. Curr. Opin. Cell Biol. 16, 451-457.[CrossRef][Medline]
Seabra, M. C., Brown, M. S., Slaughter, C. A., Sudhof, T. C. and Goldstein, J. L. (1992). Purification of component A of Rab geranylgeranyl transferase: possible identity with the choroideremia gene product. Cell 70, 1049-1057.[CrossRef][Medline]
Seabra, M. C., Brown, M. S. and Goldstein, J. L. (1993). Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase. Science 259, 377-381.
Seabra, M. C., Ho, Y. K. and Anant, J. S. (1995). Deficient geranylgeranylation of Ram/Rab27 in choroideremia. J. Biol. Chem. 270, 24420-24427.
Sheen, V. L., Ganesh, V. S., Topcu, M., Sebire, G., Bodell, A., Hill, R. S., Grant, P. E., Shugart, Y. Y., Imitola, J., Khoury, S. J. et al. (2004). Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex. Nat. Genet. 36, 69-76.[CrossRef][Medline]
Shirakawa, R., Higashi, T., Tabuchi, A., Yoshioka, A., Nishioka, H., Fukuda, M., Kita, T. and Horiuchi, H. (2004). Munc13-4 is a GTP-Rab27-binding protein regulating dense core granule secretion in platelets. J. Biol. Chem. 279, 10730-10737.
Shoulders, C. C., Stephens, D. J. and Jones, B. (2004). The intracellular transport of chylomicrons requires the small GTPase, Sar1b. Curr. Opin. Lipidol. 15, 191-197.[CrossRef][Medline]
Siddiqi, S. A., Gorelick, F. S., Mahan, J. T. and Mansbach, C. M. 2nd. (2003). COPII proteins are required for Golgi fusion but not for endoplasmic reticulum budding of the pre-chylomicron transport vesicle. J. Cell Sci. 116, 415-427.
Siddiqi, S. A., Siddiqi, S., Mahan, J., Peggs, K., Gorelick, F. S. and Mansbach, C. M. (2006). The identification of a novel ER to Golgi SNARE complex used by the Pre-chylomicron transport vesicle. J. Biol. Chem. 281, 20974-20982.
Skehel, P. A., Fabian-Fine, R. and Kandel, E. R. (2000). Mouse VAP33 is associated with the endoplasmic reticulum and microtubules. Proc. Natl. Acad. Sci. USA 97, 1101-1106.
Smith, R., Brundin, P. and Li, J. Y. (2005). Synaptic dysfunction in Huntington's disease: a new perspective. Cell. Mol. Life Sci. 62, 1901-1912.[CrossRef][Medline]
Sprecher, E., Ishida-Yamamoto, A., Mizrahi-Koren, M., Rapaport, D., Goldsher, D., Indelman, M., Topaz, O., Chefetz, I., Keren, H., O'Brien T, J. et al. (2005). A mutation in SNAP29, coding for a SNARE protein involved in intracellular trafficking, causes a novel neurocutaneous syndrome characterized by cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma. Am. J. Hum. Genet. 77, 242-251.[CrossRef][Medline]
Spritz, R. A. (1998). Genetic defects in Chediak-Higashi syndrome and the beige mouse. J. Clin. Immunol. 18, 97-105.[CrossRef][Medline]
Stinchcombe, J. C., Barral, D. C., Mules, E. H., Booth, S., Hume, A. N., Machesky, L. M., Seabra, M. C. and Griffiths, G. M. (2001). Rab27a is required for regulated secretion in cytotoxic T lymphocytes. J. Cell. Biol. 152, 825-834.
Strom, M., Hume, A. N., Tarafder, A. K., Barkagianni, E. and Seabra, M. C. (2002). A family of Rab27-binding proteins. Melanophilin links Rab27a and myosin Va function in melanosome transport. J. Biol. Chem. 277, 25423-25430.
Su, Q., Mochida, S., Tian, J. H., Mehta, R. and Sheng, Z. H. (2001). SNAP-29: a general SNARE protein that inhibits SNARE disassembly and is implicated in synaptic transmission. Proc. Natl. Acad. Sci. USA 98, 14038-14043.
Suchy, S. F., Olivos-Glander, I. M. and Nussabaum, R. L. (1995). Lowe syndrome, a deficiency of phosphatidylinositol 4,5-bisphosphate 5-phosphatase in the Golgi apparatus. Hum. Mol. Genet. 4, 2245-2250.
Südhof, T. C. (2004). The synaptic vesicle cycle. Annu. Rev. Neurosci. 27, 509-547.[CrossRef][Medline]
Sugie, K., Noguchi, S., Kozuka, Y., Arikawa-Hirasawa, E., Tanaka, M., Yan, C., Saftig, P., von Figura, K., Hirano, M., Ueno, S. et al. (2005). Autophagic vacuoles with sarcolemmal features delineate Danon disease and related myopathies. J. Neuropathol. Exp. Neurol. 64, 513-522.[Medline]
Swayne, L. A., Chen, L., Hameed, S., Barr, W., Charlesworth, E., Colicos, M. A., Zamponi, G. W. and Braun, J. E. (2005). Crosstalk between huntingtin and syntaxin 1A regulates N-type calcium channels. Mol. Cell. Neurosci. 30, 339-351.[CrossRef][Medline]
Thompson, H. M., Cao, H., Chen, J., Euteneuer, U. and McNiven, M. A. (2004). Dynamin 2 binds gamma-tubulin and participates in centrosome cohesion. Nat. Cell. Biol. 6, 335-342.[CrossRef][Medline]
Tiede, S., Storch, S., Lubke, T., Henrissat, B., Bargal, R., Raas-Rothschild, A. and Braulke, T. (2005). Mucolipidosis II is caused by mutations in GNPTA encoding the alpha/beta GlcNAc-1-phosphotransferase. Nat. Med. 11, 1109-1112.[CrossRef][Medline]
Tiller, G. E., Hannig, V. L., Dozier, D., Carrel, L., Trevarthen, K. C., Wilcox, W. R., Mundlos, S., Haines, J. L., Gedeon, A. K. and Gecz, J. (2001). A recurrent RNA-splicing mutation in the SEDL gene causes X-linked spondyloepiphyseal dysplasia tarda. Am. J. Hum. Genet. 68, 1398-1407.[CrossRef][Medline]
Trotta, N., Orso, G., Rossetto, M. G., Daga, A. and Broadie, K. (2004). The hereditary spastic paraplegia gene, spastin, regulates microtubule stability to modulate synaptic structure and function. Curr. Biol. 14, 1135-1147.[CrossRef][Medline]
Ueno, S., Maruki, Y., Nakamura, M., Tomemori, Y., Kamae, K., Tanabe, H., Yamashita, Y., Matsuda, S., Kaneko, S. and Sano, A. (2001). The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat. Genet. 28, 121-122.[CrossRef][Medline]
Ungermann, C. and Langosch, D. (2005). Functions of SNAREs in intracellular membrane fusion and lipid bilayer mixing. J. Cell. Sci. 118, 3819-3828.
Ungewickell, A., Ward, M. E., Ungewickell, E. and Majerus, P. W. (2004). The inositol polyphosphate 5-phosphatase Ocrl associates with endosomes that are partially coated with clathrin. Proc. Natl. Acad. Sci. USA 101, 13501-13506.
Valdez, A. C., Cabaniols, J. P., Brown, M. J. and Roche, P. A. (1999). Syntaxin 11 is associated with SNAP-23 on late endosomes and the trans-Golgi network. J. Cell Sci. 112, 845-854.[Abstract]
Valera, A. G., Diaz-Hernandez, M., Hernandez, F., Ortega, Z. and Lucas, J. J. (2005). The ubiquitin-proteasome system in Huntington's disease. Neuroscientist 11, 583-594.
Wei, M. L. (2006). Hermansky-Pudlak syndrome: a disease of protein trafficking and organelle function. Pigment. Cell. Res. 19, 19-42.[CrossRef][Medline]
Velayos-Baeza, A., Vettori, A., Copley, R. R., Dobson-Stone, C. and Monaco, A. P. (2004). Analysis of the human VPS13 gene family. Genomics 84, 536-549.[CrossRef][Medline]
Verhoeven, K., De Jonghe, P., Coen, K., Verpoorten, N., Auer-Grumbach, M., Kwon, J. M., FitzPatrick, D., Schmedding, E., De Vriendt, E., Jacobs, A. et al. (2003). Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am. J. Hum. Genet. 72, 722-727.[CrossRef][Medline]
Whyte, J. R. and Munro, S. (2002). Vesicle tethering complexes in membrane traffic. J. Cell. Sci. 115, 2627-2637.
Wienecke, R., Konig, A. and DeClue, J. E. (1995). Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J. Biol. Chem. 270, 16409-16414.
Wu, X., Bowers, B., Rao, K., Wei, Q. and Hammer, J. A., 3rd. (1998). Visualization of melanosome dynamics within wild-type and dilute melanocytes suggests a paradigm for myosin V function in vivo. J. Cell. Biol. 143, 1899-1918.
Wu, X., Wang, F., Rao, K., Sellers, J. R. and Hammer, J. A., 3rd. (2002). Rab27a is an essential component of melanosome receptor for myosin Va. Mol. Biol. Cell. 13, 1735-1749.
Xiao, G. H., Shoarinejad, F., Jin, F., Golemis, E. A. and Yeung, R. S. (1997). The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J. Biol. Chem. 272, 6097-6100.
Xu, K. F., Shen, X., Li, H., Pacheco-Rodriguez, G., Moss, J. and Vaughan, M. (2005). Interaction of BIG2, a brefeldin A-inhibited guanine nucleotide-exchange protein, with exocyst protein Exo70. Proc. Natl. Acad. Sci. USA 102, 2784-2789.
Zerial, M. and McBride, H. (2001). Rab proteins as membrane organizers. Nat. Rev. Mol. Cell Biol. 2, 107-117.[CrossRef][Medline]
Zhang, B., Cunningham, M. A., Nichols, W. C., Bernat, J. A., Seligsohn, U., Pipe, S. W., McVey, J. H., Schulte-Overberg, U., de Bosch, N. B., Ruiz-Saez, A. et al. (2003). Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat. Genet. 34, 220-225.[CrossRef][Medline]
Zhang, B., Kaufman, R. J. and Ginsburg, D. (2005). LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J. Biol. Chem. 280, 25881-25886.
Zhang, B., McGee, B., Yamaoka, J. S., Guglielmone, H., Downes, K. A., Minoldo, S., Jarchum, G., Peyvandi, F., de Bosch, N. B., Ruiz-Saez, A. et al. (2006). Combined deficiency of factor V and factor VIII is due to mutations in either LMAN1 or MCFD2. Blood 107, 1903-1907.
Zhang, X., Jefferson, A. B., Auethavekiat, V. and Majerus, P. W. (1995). The protein deficient in Lowe syndrome is a phosphatidylinositol-4,5-bisphosphate 5-phosphatase. Proc. Natl. Acad. Sci. USA 92, 4853-4856.
Zhao, C., Takita, J., Tanaka, Y., Setou, M., Nakagawa, T., Takeda, S., Yang, H. W., Terada, S., Nakata, T., Takei, Y. et al. (2001). Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 105, 587-597.[CrossRef][Medline]
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R. et al. (2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498.
Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B. R., Hayden, M. R., Timmusk, T. et al. (2003). Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35, 76-83.[CrossRef][Medline]
Zuchner, S., Noureddine, M., Kennerson, M., Verhoeven, K., Claeys, K., De Jonghe, P., Merory, J., Oliveira, S. A., Speer, M. C., Stenger, J. E. et al. (2005). Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat. Genet. 37, 289-294.[CrossRef][Medline]
zur Stadt, U., Schmidt, S., Kasper, B., Beutel, K., Diler, A. S., Henter, J. I., Kabisch, H., Schneppenheim, R., Nurnberg, P., Janka, G. et al. (2005). Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum. Mol. Genet. 14, 827-834.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Heuck, T.-G. Du, S. Jellbauer, K. Richter, C. Kruse, S. Jaklin, M. Muller, J. Buchner, R.-P. Jansen, and D. Niessing Monomeric myosin V uses two binding regions for the assembly of stable translocation complexes PNAS, December 11, 2007; 104(50): 19778 - 19783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Haass, M. Jonikas, P. Walter, J. S. Weissman, Y.-N. Jan, L. Y. Jan, and M. Schuldiner Identification of yeast proteins necessary for cell-surface function of a potassium channel PNAS, November 13, 2007; 104(46): 18079 - 18084. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
. d, 
3-subunit; b3A, ß3A-subunit.